P Cottagnoud
Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci
Flatz L, Cottagnoud M, Kühn F, Entenza J, Stucki A, Cottagnoud P. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci. J Antimicrob Chemother 2004; 53:305-10.
16.01.2004Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci
16.01.2004J Antimicrob Chemother 2004; 53:305-10
Flatz Lukas, Cottagnoud M, Kühn F, Entenza J, Stucki A, Cottagnoud P
Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis
Cottagnoud P, Cottagnoud M, Acosta F, Flatz L, Kühn F, Stucki A, Entenza J. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis. Eur J Clin Microbiol Infect Dis 2003; 22:656-62.
14.10.2003Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis
14.10.2003Eur J Clin Microbiol Infect Dis 2003; 22:656-62
Cottagnoud P, Cottagnoud M, Acosta F, Flatz Lukas, Kühn F, Stucki A, Entenza J
Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro
Kühn F, Cottagnoud M, Acosta F, Flatz L, Entenza J, Cottagnoud P. Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro. Antimicrob Agents Chemother 2003; 47:2487-91.
01.08.2003Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro
01.08.2003Antimicrob Agents Chemother 2003; 47:2487-91
Kühn F, Cottagnoud M, Acosta F, Flatz Lukas, Entenza J, Cottagnoud P
Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation
Emmenegger U, Spaeth P, Cerny A, Cottagnoud P, Semela D, Bihl F, Fux C, Frey U, Reimers A, Neftel K. Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly 2002; 132:230-6.
04.05.2002Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation
04.05.2002Swiss Med Wkly 2002; 132:230-6
Emmenegger U, Spaeth P J, Cerny A, Cottagnoud P, Semela David, Bihl F, Fux Ch, Frey U, Reimers A, Neftel Klaus A
Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes
Emmenegger U, Frey U, Reimers A, Fux C, Semela D, Cottagnoud P, Spaeth P, Neftel K. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol 2001; 68:4-10.
01.09.2001Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes
01.09.2001Am J Hematol 2001; 68:4-10
Emmenegger U, Frey U, Reimers A, Fux C, Semela David, Cottagnoud P, Spaeth P J, Neftel K A